



# Antimicrobial Susceptibility of Clinical Isolates of *Bacteroides fragilis* Group Organisms Recovered from 2009 to 2012 in a Korean Hospital

Jisook Yim, M.D.<sup>1</sup>, Yangsoon Lee, M.D.<sup>2</sup>, Myungsook Kim, M.T.<sup>1</sup>, Young Hee Seo, B.S.<sup>1</sup>, Wan Hee Kim, B.S.<sup>1</sup>, Dongeun Yong, M.D.<sup>1</sup>, Seok Hoon Jeong, M.D.<sup>1</sup>, Kyungwon Lee, M.D.<sup>1</sup>, and Yunsop Chong, Ph.D.<sup>1</sup>

Department of Laboratory Medicine and Research Institute of Bacterial Resistance<sup>1</sup>, Yonsei University College of Medicine, Seoul; Department of Laboratory Medicine<sup>2</sup>, Hanyang University College of Medicine, Seoul, Korea

**Background:** Periodic monitoring of antimicrobial resistance trends of clinically important anaerobic bacteria such as *Bacteroides fragilis* group organisms is required. We determined the antimicrobial susceptibilities of clinical isolates of *B. fragilis* group organisms recovered from 2009 to 2012 in a tertiary-care hospital in Korea.

**Methods:** A total of 180 nonduplicate clinical isolates of *B. fragilis* group organisms were collected in a tertiary care hospital. The species were identified by conventional methods: the ATB 32A rapid identification system (bioMérieux, France) and the Vitek MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (bioMérieux). Antimicrobial susceptibility was determined by the CLSI agar dilution method.

**Results:** Imipenem and meropenem resistance rates were 0-6% for *B. fragilis* group isolates. The rate of resistance to piperacillin-tazobactam was 2% for *B. fragilis* and 0% for other *Bacteroides* species, but 17% for *B. thetaiotaomicron* isolates. High resistance rates to piperacillin (72% and 69%), cefotetan (89% and 58%), and clindamycin (83% and 69%) were observed for *B. thetaiotaomicron* and other *Bacteroides* spp. The moxifloxacin resistance rate was 27% for other *Bacteroides* spp. The MIC<sub>50</sub> and MIC<sub>90</sub> of tigecycline were 2-4 µg/mL and 8-16 µg/mL, respectively. No isolates were resistant to chloramphenicol or metronidazole.

**Conclusions:** Imipenem, meropenem, chloramphenicol, and metronidazole remain active against *B. fragilis* group isolates. Moxifloxacin and tigecycline resistance rates are 2-27% and 8-15% for *B. fragilis* group isolates, respectively.

**Key Words:** *Bacteroides fragilis* group, Antimicrobial resistance, Tigecycline, Moxifloxacin

**Received:** July 25, 2014

**Revision received:** September 16, 2014

**Accepted:** October 30, 2014

**Corresponding author:** Kyungwon Lee  
Department of Laboratory Medicine,  
Research Institute of Bacterial Resistance,  
Yonsei University College of Medicine, 50-1  
Yonsei-ro, Seodaemun-gu, Seoul 120-752,  
Korea

Tel: +82-2-2228-2446

Fax: +82-2-313-0956

E-mail: leekcp@yuhs.ac

© The Korean Society for Laboratory Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## INTRODUCTION

*Bacteroides fragilis* group organisms are important anaerobic pathogens that frequently cause various infections such as intra-abdominal infection, postoperative wound infection, and bacteremia in humans [1-4]. These organisms are the most antibiotic-resistant among the anaerobic isolates and are responsible for high rates of morbidity and mortality [4-6].

According to the CLSI guidelines, routine susceptibility testing may not be necessary for many individual patient isolates [7-9], because predicting and testing the susceptibility of anaerobes is technically difficult and time-consuming. However, antimicrobial resistance of *B. fragilis* group organisms varies by geographic location and species [1, 2, 5, 7, 10]. Furthermore, antimicrobial resistance of these organisms has consistently increased over the past few decades, and their susceptibility to antimicrobial

agents has become less predictable. Therefore, periodic and local surveillance studies are considered necessary, and current susceptibility data are important for empirical antimicrobial therapy.

Most susceptibility studies use the CLSI methodology. However, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) publishes its own breakpoints, not all of which are equivalent to those of the CLSI [11]. Therefore, resistance rates may differ depending on the breakpoint used.

In this study, we determined the current susceptibilities of clinical isolates of the *B. fragilis* group organisms recovered in a tertiary-care hospital in Korea from 2009 to 2012, and we compared the resistant rates using both the CLSI and EUCAST breakpoints.

## METHODS

### 1. Bacterial isolates

*B. fragilis* group organisms were isolated from blood, normally sterile body fluid, and abscess specimens in a university hospital in Korea between 2009 and 2012. All isolates were identified by conventional methods, a commercial rapid identification kit (ATB 32A, ANC; bioMérieux, Marcy l'Etoile, France) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Vitek MS, bioMérieux). A total of 180 nonduplicate isolates were used in this study, including 86 *B. fragilis*, 46 *B. thetaiotaomicron*, 20 *Bacteroides vulgatus*, 13 *Bacteroides ovatus*, 13 *Parabacteroides distasonis* and 2 *Bacteroides uniformis* isolates.

### 2. Antimicrobial susceptibility testing

Antimicrobial susceptibility was determined by the CLSI agar dilution method [9]. The medium used was *Brucella* agar (Becton Dickinson, Cockeysville, MD, USA) supplemented with 5 µg/mL hemin, 1 µg/mL vitamin K1, and 5% laked sheep blood. The antimicrobials used were piperacillin and tazobactam (Yuhan, Seoul, Korea), cefoxitin (Merck Sharp & Dohme, West Point, PA, USA), cefotetan (Daiichi Pharmaceutical, Tokyo, Japan), clindamycin (Korea Upjohn, Seoul, Korea), imipenem and meropenem (Sumitomo, Tokyo, Japan), moxifloxacin (Bayer Korea, Seoul, Korea) and tigecycline (Wyeth Research, Pearl River, NY, USA); they were used in the powder form.

For piperacillin-tazobactam, serial two-fold dilutions of piperacillin were combined with tazobactam at constant concentra-

tions of 4 µg/mL.

The plates were inoculated with 10<sup>5</sup> colony-forming unit (CFU) with a Steers replicator (Craft Machine Inc., Woodline, PA, USA) and incubated in an anaerobic chamber (Forma Scientific, Marietta, OH, USA) for 48 hr at 37°C. The minimum inhibitory concentration (MIC) was defined as the lowest antibiotic concentration that caused a marked reduction in growth, such as from confluent growth to a haze, less than 10 tiny colonies, or several normal-sized colonies [9]. *B. fragilis* ATCC 25285 and *B. thetaiotaomicron* ATCC 29741 were used as controls. The MICs were interpreted using the breakpoints recommended by CLSI and EUCAST for anaerobic bacteria [9, 13]. Since neither CLSI nor EUCAST recommends breakpoints for tigecycline, the breakpoints recommended by the US Food and Drug Administration (FDA), ≤4 and ≥16 µg/mL, were used [12].

## RESULTS

MIC ranges, MIC<sub>50</sub>s, MIC<sub>90</sub>s, and the percentages of resistant isolates for various antimicrobial agents are shown in Table 1.

Imipenem resistance rates were less than 5% for *B. fragilis* group isolates. There were four imipenem-resistant isolates: one *B. fragilis*, two *B. thetaiotaomicron*, and one *B. ovatus*. The resistance rates to meropenem were 0-6% for all tested *B. fragilis* group organisms. High resistance rates to piperacillin were observed (72% and 69%) for *B. thetaiotaomicron* isolates and other *Bacteroides* spp., respectively. The rate of resistance to piperacillin-tazobactam was 2% for *B. fragilis*, 0% for other *Bacteroides* spp., and 17% for *B. thetaiotaomicron* isolates. Cefoxitin is an active β-lactam drug used against *B. fragilis* group organisms, but our results showed an increase in resistance rates to this drug. The rates of resistance to cefotetan (89% and 58%) increased prominently for *B. thetaiotaomicron* isolates and other *Bacteroides* spp., respectively. The resistance rates for clindamycin were 83% and 69% for *B. thetaiotaomicron* and other *Bacteroides* spp., respectively. The resistance rates for moxifloxacin were 8%, 2%, and 27% for *B. fragilis*, *B. thetaiotaomicron*, and other *Bacteroides* spp., respectively. The MIC range for tigecycline was ≤0.06-32 µg/mL for all *B. fragilis* group isolates. The resistance rates of tigecycline were 15%, 13%, and 8% for *B. fragilis*, *B. thetaiotaomicron*, and other *Bacteroides* spp., respectively.

All the isolates were inhibited by ≤8 µg/mL chloramphenicol or metronidazole, to which no isolates were resistant.

The EUCAST breakpoints were equal to or lower than the CLSI breakpoints for most antibiotics tested in this study. Large

**Table 1.** Antimicrobial activity against 180 *Bacteroides fragilis* group organisms isolated from 2009 to 2012 in a Korean tertiary care university hospital

Organism (N of isolates) and antimicrobial agent	MIC ( $\mu\text{g/mL}$ )			CLSI ( $\mu\text{g/mL}$ )				EUCAST ( $\mu\text{g/mL}$ )			
				Susceptibility		Susceptibility (%)		Breakpoints		Susceptibility (%)	
	Range	MIC <sub>50</sub>	MIC <sub>90</sub>	S	R	S	R	S	R	S	R
<i>Bacteroides fragilis</i> (86)											
Piperacillin	2->256	8	>256	≤32	≥128	69	24	≤16	>16	67	33
Piperacillin-tazobactam	≤0.06->128	0.5	2	≤32	≥128	98	2	≤8	>16	98	2
Cefoxitin	4-128	8	32	≤16	≥64	88	3	- <sup>†</sup>	-	-	-
Cefotetan	2->128	8	64	≤16	≥64	84	13	-	-	-	-
Imipenem	0.06->128	0.12	1	≤4	≥16	99	1	≤2	>8	97	1
Meropenem	0.12->128	0.25	4	≤4	≥16	91	6	≤2	>8	86	6
Clindamycin	≤0.06->128	1	>128	≤2	≥8	60	35	≤4	>4	65	35
Moxifloxacin	0.25-32	0.5	2	≤2	≥8	91	8	-	-	-	-
Chloramphenicol	4-8	4	8	≤8	≥32	100	0	≤8	>8	100	0
Metronidazole	0.5-4	2	4	≤8	≥32	100	0	≤4	>4	100	0
Tigecycline*	0.5-32	2	16	≤4	≥16	67	15	≤4	≥16	67	15
<i>Bacteroides thetaiotaomicron</i> (46)											
Piperacillin	16->256	>256	>256	≤32	≥128	24	72	≤16	>16	2	98
Piperacillin-tazobactam	4->128	16	>128	≤32	≥128	83	17	≤8	>16	24	41
Cefoxitin	16->128	32	64	≤16	≥64	24	15	-	-	-	-
Cefotetan	32->128	64	>128	≤16	≥64	0	89	-	-	-	-
Imipenem	0.12-32	0.5	8	≤4	≥16	87	4	≤2	>8	83	4
Meropenem	0.25-4	0.5	2	≤4	≥16	100	0	≤2	>8	91	0
Clindamycin	4->128	>128	>128	≤2	≥8	0	83	≤4	>4	17	83
Moxifloxacin	0.5-32	2	4	≤2	≥8	87	2	-	-	-	-
Chloramphenicol	4-8	8	8	≤8	≥32	100	0	≤8	>8	100	0
Metronidazole	0.5-4	2	4	≤8	≥32	100	0	≤4	>4	100	0
Tigecycline	0.5-16	4	16	≤4	≥16	67	13	≤4	≥16	67	13
Other <i>Bacteroides</i> species (48)											
Piperacillin	≤1->256	>256	>256	≤32	≥128	31	69	≤16	>16	31	69
Piperacillin-tazobactam	≤0.06-64	4	32	≤32	≥128	98	0	≤8	>16	81	13
Cefoxitin	≤1->128	16	64	≤16	≥64	67	15	-	-	-	-
Cefotetan	2->128	64	>128	≤16	≥64	27	58	-	-	-	-
Imipenem	0.06-32	0.5	2	≤4	≥16	98	2	≤2	>8	98	2
Meropenem	0.03-64	0.5	2	≤4	≥16	94	2	≤2	>8	92	2
Clindamycin	≤0.06->128	>128	128	≤2	≥8	31	69	≤4	>4	31	69
Moxifloxacin	≤0.06-128	1	32	≤2	≥8	69	27	-	-	-	-
Chloramphenicol	1-8	4	8	≤8	≥32	100	0	≤8	>8	100	0
Metronidazole	≤0.12-4	2	2	≤8	≥32	100	0	≤4	>4	100	0
Tigecycline	≤0.06-16	4	8	≤4	≥16	67	8	≤4	≥16	67	8

\*No CLSI or EUCAST breakpoints available; FDA breakpoints were used. <sup>†</sup>No EUCAST breakpoints available.

Abbreviations: MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing; S, susceptible; R, resistant.

differences in resistance rates when analyzed with CLSI or EUCAST breakpoints were observed for piperacillin: 24% vs. 33% for *B. fragilis* and 72% vs. 98% for *B. thetaiotaomicron*, respectively. The piperacillin-tazobactam resistance rates were 17% vs. 41% for *B. thetaiotaomicron* and 0% vs. 13% for other *Bacteroides* species by CLSI or EUCAST breakpoints, respectively. No other resistance rates differed by CLSI or EUCAST.

## DISCUSSION

Susceptibility testing had not been routinely used for treating infections involving anaerobes because of the availability of broad-spectrum antibiotics, delayed reporting due to slow growth of bacteria, and the assumption that anaerobe susceptibility patterns do not change [13, 14]. However, antimicrobial susceptibility testing is indispensable in patients with serious or life-threatening infections, because the clinical outcome correlates with the test results [14, 15]. In addition, an increasing resistance of anaerobes to several antibiotics has recently been reported [3, 7, 11].

Carbapenems are usually highly active against *B. fragilis* group isolates. A study performed from 1989 to 1990 found no carbapenem-resistant *B. fragilis* group isolates [16]. Although the level of carbapenem resistance has not changed markedly during the past 25 yr, the percentage of isolates with reduced susceptibilities has steadily increased. In this study, the meropenem resistance rate was 6% for *B. fragilis* isolates. This rate is higher than the approximately 1% rate reported for *B. fragilis* in Europe, USA, and Canada, but lower than the rate (7.5%) reported in Germany by Seifert *et al.* [10]. Piperacillin resistance increased to 72% and 69% for *B. thetaiotaomicron* and other *Bacteroides* group spp., respectively, which are higher than the rates reported 10 yr ago (42% and 49%, respectively). A study performed from 1997 to 2004 reported the MIC<sub>90</sub> and resistance rate to piperacillin-tazobactam to be 16 µg/mL and 4% [6]; in this study, they were found to increase to >128 µg/mL and 17%, respectively, for *B. thetaiotaomicron*. These rates were slightly higher than that reported for piperacillin-tazobactam in a multicenter survey of 13 European countries; the reported MIC<sub>90</sub> was 128 µg/mL and the resistance rate was 12% [3]. Other countries, such as the USA, Canada, and Argentina, have reported relatively low piperacillin-tazobactam resistance rates (<4%) for all *B. fragilis* group isolates [2, 7, 14]. Compared to cefoxitin, cefotetan is less effective against *B. fragilis* group isolates. Recently, the Infectious Diseases Society of America (IDSA) removed cefotetan from its list of recommended therapies for intra-abdominal infections because it has poor activity

against the *B. fragilis* group and results in clinical failures [11]. The present study also reported a poor activity of cefotetan; the resistance rates were 89% for *B. thetaiotaomicron* and 58% for other *B. fragilis* group organisms.

Moxifloxacin had good *in vitro* activity against most anaerobic bacteria when first introduced [15]; however, various recent surveys have reported increased resistance among *Bacteroides* spp. [2, 3, 10, 14, 16, 17]. Our previous studies also reported increased resistance to moxifloxacin among *Bacteroides* species and found a resistance rate of 11-20% in *B. fragilis* [8, 17]. However, the present data for moxifloxacin show low resistance (8% and 2%, respectively) for *B. fragilis* and *B. thetaiotaomicron* and a relatively high resistance rate (27%) in other *Bacteroides* species (Table 1).

Tigecycline has been approved by the FDA for use in complicated skin and soft tissue infections and intra-abdominal infections. Despite expectations, tigecycline resistance rates were 8-15% for *B. fragilis* group species in this study. Some studies have shown variable resistance rates, such as 0-10% in Europe and Argentina [3, 7] and 0-17.5% in Canada [2]. In addition, this study found a relatively high percentage of intermediate rates (17-25% for all *B. fragilis* group isolates); therefore, continuous attention is required.

Metronidazole and chloramphenicol resistance in *B. fragilis* group isolates have recently been reported worldwide [3, 10, 15, 18, 19]. Resistance to metronidazole was recently reported to be <1% in Europe and the USA [3, 14], but it has been approaching 1% in many European countries [10]. However, no *B. fragilis* group isolates that are resistant to these agents have been reported previously in Korea. Consistent with previous reports [6, 8, 17, 20], susceptibility patterns for metronidazole and chloramphenicol remained stable.

To compare the differences between using CLSI and EUCAST clinical breakpoints, the available EUCAST breakpoints were also used. EUCAST breakpoints were not available for cefoxitin, cefotetan, moxifloxacin, and tigecycline. EUCAST stated that there is insufficient evidence that anaerobes are a good target for therapy with moxifloxacin [13]. They also stated that there is clinical evidence of tigecycline activity in mixed intra-abdominal infections, but no correlation between MIC values and clinical outcomes; therefore, no breakpoints were given [13]. The most prominent difference between CLSI and EUCAST is the higher CLSI breakpoint for piperacillin and piperacillin-tazobactam. We expected higher resistance rates according to the EUCAST breakpoints; however, only the piperacillin and piperacillin-tazobactam resistance patterns differed significantly.

In conclusion, imipenem, meropenem, chloramphenicol, and metronidazole remain active against *B. fragilis* group isolates. Moxifloxacin resistance rates were 8%, 2%, and 27% for *B. fragilis*, *B. thetaiotaomicron*, and other *Bacteroides* spp., respectively. Tigecycline resistance rates for *B. fragilis* group species were 8-15%. Therefore, periodic monitoring is needed to demonstrate changes in the antimicrobial susceptibility patterns of *B. fragilis* group isolates.

### Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

### Acknowledgments

This study was supported by a CMB-Yuhan research grant of Yonsei University College of Medicine for 2012(6-2012-0048).

### REFERENCES

1. Treviño M, Areses P, Peñalver MD, Cortizo S, Pardo F, del Molino ML, et al. Susceptibility trends of *Bacteroides fragilis* group and characterization of carbapenemase-producing strains by automated REP-PCR and MALDI TOF. *Anaerobe* 2012;18:37-43.
2. Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG. Prevalence of antimicrobial resistance among clinical isolates of *Bacteroides fragilis* group in Canada in 2010-2011: CANWARD surveillance study. *Antimicrob Agents Chemother* 2012;56:1247-52.
3. Nagy E, Urbán E, Nord CE. Antimicrobial susceptibility of *Bacteroides fragilis* group isolates in Europe: 20 years of experience. *Clin Microbiol Infect* 2011;17:371-9.
4. Fille M, Mango M, Lechner M, Schaumann R. *Bacteroides fragilis* group: trends in resistance. *Curr Microbiol* 2006;52:153-7.
5. Snyderman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, et al. National survey on the susceptibility of *Bacteroides fragilis* group: report and analysis of trends in the United States from 1997 to 2004. *Antimicrob Agents Chemother* 2007;51:1649-55.
6. Roh K, Kim S, Kim CK, Yum JH, Kim MS, Yong D, et al. Resistance trends of *Bacteroides fragilis* group over an 8-year period, 1997-2004, in Korea. *Korean J Lab Med* 2009;29:293-8.
7. Fernández-Canigia L, Litterio M, Legaria MC, Castello L, Predari SC, Di Martino A, et al. First national survey of antibiotic susceptibility of the *Bacteroides fragilis* group: emerging resistance to carbapenems in Argentina. *Antimicrob Agents Chemother* 2012;56:1309-14.
8. Lee Y, Park Y, Kim MS, Yong D, Jeong SH, Lee K, et al. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. *Antimicrob Agents Chemother* 2010;54:3993-7.
9. CLSI. Methods for Antimicrobial susceptibility testing of anaerobic bacteria; Approved standard, 8<sup>th</sup> ed. CLSI document M11-A8. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
10. Seifert H and Dalhoff A. German multicentre survey of the antibiotic susceptibility of *Bacteroides fragilis* group and *Prevotella* species isolated from intra-abdominal infections: results from the PRISMA study. *J Antimicrob Chemother* 2010;65:2405-10.
11. Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. *Clin Microbiol Rev* 2013;26:526-46.
12. The US Food and Drug Administration. FDA Approved Drug Products Label for TYGACIL, NDA no. 021821 (approved on 23/05/2013). [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/021821s0371bl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s0371bl.pdf)
13. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, 2013. [http://www.eucast.org/clinical\\_breakpoints/](http://www.eucast.org/clinical_breakpoints/)
14. Snyderman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). *Clin Infect Dis* 2010;50(SI):S26-33.
15. Goldstein EJC and Citron DM. Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part II. *Clinical Microbiology Newsletter* 2011;33:9-15.
16. Betriu C, Rodríguez-Avial I, Gómez M, Culebras E, Picazo JJ. Changing patterns of fluoroquinolone resistance among *Bacteroides fragilis* group organisms over a 6-year period (1997-2002). *Diagn Microbiol Infect Dis* 2005;53:221-3.
17. Cho S, Chung HS, Lee Y, Kim M, Yong D, Jeong SH, et al. In vitro activities of ceftriaxone-sulbactam against major aerobic and anaerobic bacteria from clinical samples. *Lab Med Online* 2011;1:209-20.
18. Wybo I, Van den Bossche D, Soetens O, Vekens E, Vandoorlaer K, Claeys G, et al. Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. *J Antimicrob Chemother* 2014;69:155-61.
19. Brazier JS, Stubbs SL, Duerden BI. Metronidazole resistance among clinical isolates belonging to the *Bacteroides fragilis* group: time to be concerned? *J Antimicrob Chemother* 1999;44:580-1.
20. Lee K, Shin HB, Chong Y. Antimicrobial resistance patterns of *Bacteroides fragilis* group organisms in Korea. *Yonsei Med J* 1998;39:578-86.